Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer (SIMPHONY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03324425
Recruitment Status : Recruiting
First Posted : October 27, 2017
Last Update Posted : April 5, 2022
Information provided by (Responsible Party):
Mothaffar Rimawi, Baylor Breast Care Center

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 2028
Estimated Study Completion Date : December 2030